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Antibiotics as Part of the Management
of Severe Acute Malnutrition
Indi Trehan, M.D., M.P.H., D.T.M.&H., Hayley S. Goldbach, Sc.B.,
Lacey N. LaGrone, M.D., Guthrie J. Meuli, B.S., Richard J. Wang, M.D.,
Kenneth M. Maleta, M.B., B.S., Ph.D., and Mark J. Manary, M.D.

A BS T R AC T
BACKGROUND

Severe acute malnutrition contributes to 1 million deaths among children annually.
Adding routine antibiotic agents to nutritional therapy may increase recovery rates
and decrease mortality among children with severe acute malnutrition treated in
the community.
METHODS

In this randomized, double-blind, placebo-controlled trial, we randomly assigned
Malawian children, 6 to 59 months of age, with severe acute malnutrition to receive
amoxicillin, cefdinir, or placebo for 7 days in addition to ready-to-use therapeutic
food for the outpatient treatment of uncomplicated severe acute malnutrition. The
primary outcomes were the rate of nutritional recovery and the mortality rate.
RESULTS

A total of 2767 children with severe acute malnutrition were enrolled. In the amoxicillin, cefdinir, and placebo groups, 88.7%, 90.9%, and 85.1% of the children recovered, respectively (relative risk of treatment failure with placebo vs. amoxicillin, 1.32;
95% confidence interval [CI], 1.04 to 1.68; relative risk with placebo vs. cefdinir,
1.64; 95% CI, 1.27 to 2.11). The mortality rates for the three groups were 4.8%,
4.1%, and 7.4%, respectively (relative risk of death with placebo vs. amoxicillin,
1.55; 95% CI, 1.07 to 2.24; relative risk with placebo vs. cefdinir, 1.80; 95% CI, 1.22
to 2.64). Among children who recovered, the rate of weight gain was increased
among those who received antibiotics. No interaction between type of severe acute
malnutrition and intervention group was observed for either the rate of nutritional
recovery or the mortality rate.
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CONCLUSIONS

The addition of antibiotics to therapeutic regimens for uncomplicated severe acute
malnutrition was associated with a significant improvement in recovery and mortality rates. (Funded by the Hickey Family Foundation and others; ClinicalTrials.gov
number, NCT01000298.)
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he contribution of severe acute
malnutrition to the overall burden of childhood morbidity and mortality is enormous, with more than 20 million children with
severe wasting worldwide,1 an untold number
with kwashiorkor, and case fatality rates among
hospitalized children that are as high as 50%.1,2
For decades, the primary management for severe acute malnutrition was based on inpatient
rehabilitation with fortified milk formulas.3 However, international consensus guidelines now
recommend the use of ready-to-use therapeutic
food (RUTF) — usually a fortified spread consisting of peanut paste, milk powder, oil, sugar, and
a micronutrient supplement — in outpatient settings as the preferred management for uncomplicated cases of severe acute malnutrition.4 Despite the markedly better outcomes observed with
this revised outpatient regimen,5 10 to 15% of
children still do not recover, even in the context
of rigorously controlled clinical trials. Even modest improvements in recovery and mortality rates
could mean thousands of lives saved annually.
Many studies,6-15 but not all,16,17 have shown a
high prevalence of clinically significant infections
among children hospitalized for severe malnutrition. This observation has led to treatment guidelines recommending the use of routine antibiotic
agents even for children treated as outpatients,4
although outpatients are presumably much less
likely to have a systemic infection than are patients with complicated cases that require inpatient care. This recommendation for the use of
routine antibiotics is based on expert opinion and
has not been directly tested in a clinical trial18;
and observational data suggest that antibiotics are
unnecessary and perhaps even harmful in children with uncomplicated severe acute malnutrition (i.e., children with good appetite and no
clinical signs of sepsis).19
Most children with severe acute malnutrition
can now be treated in rural health posts throughout the developing world.20,21 Providing antibiotic
therapy in addition to RUTF for all malnourished
children in this setting would not only be complex and costly but arguably unnecessary or even
harmful.19 We conducted a prospective clinical
trial to determine whether the routine administration of oral antibiotics as part of the outpatient
management of severe acute malnutrition in children in Malawi was associated with improved
outcomes. Rural Malawi is representative of agrar426
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ian sub-Saharan Africa and populated primarily
by subsistence farmers.22 An estimated 11% of
the adult population in Malawi is infected with
the human immunodeficiency virus (HIV), and
53% of the children are stunted (height-for-age
z score of less than –2).23

ME THODS
STUDY POPULATION AND ELIGIBILITY

We enrolled children from December 2009 through
January 2011 at 18 feeding clinics in rural Malawi.
Each child’s weight, length, and mid-upper-arm
circumference were measured. Children who were
6 to 59 months of age, with edema (indicative of
kwashiorkor), a weight-for-height z score of less
than −3 (indicative of marasmus),24 or both (marasmic kwashiorkor), were eligible for enrollment.
Each eligible child was given a 30-g test feeding
of RUTF25 under the supervision of a nurse to
verify that the child was an appropriate candidate
for outpatient therapy. Children who were too ill
to consume the test dose in the clinic were hospitalized for inpatient management. Detailed descriptions of the study methods are provided in
the Supplementary Appendix and the study protocol, both of which are available with the full
text of this article at NEJM.org.
STUDY OVERSIGHT

The study was approved by ethics boards of the
University of Malawi, Washington University in St.
Louis, and the Malawi government. A data and
safety monitoring board monitored adverse events
and interim study outcomes. Caretakers of eligible children provided informed oral and written
consent before enrollment. Antibiotics were purchased at cost from the St. Louis Children’s Hospital Pharmacy. RUTF was purchased at cost from
Project Peanut Butter, which is based in Blantyre,
Malawi. The first and last authors vouch for the
accuracy and completeness of the data and analyses reported, as well as the fidelity of the report
to the study protocol.
STUDY DESIGN AND INTERVENTIONS

This randomized, double-blind, placebo-controlled
clinical trial compared nutritional and mortality
outcomes among children with uncomplicated
severe acute malnutrition who received treatment
as outpatients with or without antibiotics. All
children received standardized counseling and
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RUTF that provided approximately 175 kcal per
kilogram of body weight per day. One group received 80 to 90 mg of amoxicillin suspension per
kilogram per day, divided into two daily doses;
the second group received approximately 14 mg of
cefdinir suspension per kilogram per day, divided into two daily doses. A suspension of 250 mg
of amoxicillin per 5 ml was used, and the dose to
be given to each child was based on a rounded
amount that could be given by the field research
pharmacist using the markings on a plastic syringe; a similar rounding of medication dose was
used for cefdinir. The control group received placebo twice daily. Caretakers were instructed to
administer the study drug in addition to RUTF
during the initial 7 days of therapy.
STUDY PROCEDURES

Participants were assigned to their study group
when caregivers drew an opaque envelope containing one of nine coded letters corresponding
to one of the three intervention groups. Caregivers
and study personnel involved in clinical assessments and data analysis were unaware of the intervention assignments. Medications and placebo
were distributed in opaque plastic bottles, with a
plastic syringe marked with the appropriate dose
for the child. After distribution of the study interventions, nurses instructed each caretaker in the
use of the syringe to give the study medications
and supervised the administration of the first
dose in the clinic.
After enrollment and caretaker instruction,
each child was discharged home with the assigned study medication and a 2-week supply of
RUTF.25 If the household included a healthy
child who was close in age to the participant and
with whom the food might be shared, an extra
allotment of RUTF was provided. Children were
scheduled for follow-up visits at 2-week intervals,
at which time anthropometric measurements were
repeated; caretakers were also asked about the
child’s interim history and adherence to the assigned intervention.
Children who continued to have bipedal pitting edema or a weight-for-height z score below
−2 at follow-up visits24 remained in the study
and received nutritional counseling and another
2-week supply of RUTF. Any child whose condition
substantially deteriorated during the study or who
was still malnourished after six follow-up visits
was referred for inpatient care. Children who did
n engl j med 368;5

not return for follow-up visits were visited at home
by community health workers and a member of
the study team. Children were considered to
have recovered when they were without edema
and had a weight-for-height z score of −2 or
higher. Children who withdrew from the study,
were still malnourished after six follow-up visits,
were hospitalized for any reason during the
study, or died were considered to have had treatment failure.
STATISTICAL ANALYSIS

The primary end points were the nutritional recovery and mortality rates in the three study groups.
We calculated that a sample of 900 children in
each group would provide the study with 80%
power at an alpha level of 0.05 to detect a reduction of 4 percentage points in the rate of treatment failure from an estimated baseline of 11%26
and a reduction of 3.5 percentage points in the
mortality rate from an estimated baseline of 8%.
In addition, one prespecified subgroup analysis
was conducted to evaluate the interaction between
type of severe acute malnutrition and the intervention received, again with the use of recovery and
mortality rates as the primary end points. This
interaction was evaluated in a multiple logisticregression model that included baseline characteristics that were significantly correlated with the
primary outcomes in a univariate analysis.
Secondary outcomes of interest included weight
gain, length gain, whether the antibiotics were
associated with increased rates of adverse events,
and time to recovery. Intention-to-treat analyses
were used, and all tests were two-sided. Dichotomous outcomes were compared with the use of
the chi-square test and Fisher’s exact test; continuous variables were compared by means of
Student’s t-test and analysis of variance. The
relative-risk ratios for the outcomes in the three
intervention groups were also computed, and
Kaplan–Meier plots of time to recovery and time
to death were prepared.

R E SULT S
STUDY POPULATION

A total of 3212 children with severe acute malnutrition were identified from December 2009
through January 2011; after the exclusion of ineligible children, the study included 2767 children (Fig. S1 in the Supplementary Appendix).
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Table 1. Selected Baseline Characteristics of Children Enrolled in the Study.*
Characteristic

Amoxicillin
(N = 924)

Cefdinir
(N = 923)

Placebo
(N = 920)

Age — mo

20.6±9.7†

21.7±10.3

20.9±9.8
843/920 (91.6)

Mother as primary caretaker — no./total no. (%)

855/923 (92.6)

843/923 (91.3)

Current breast-feeding — no. (%)

444 (48.1)

399 (43.2)

431 (46.8)

Kwashiorkor — no. (%)

649 (70.2)

664 (71.9)

632 (68.7)

78 (8.4)

73 (7.9)

93 (10.1)

Marasmic kwashiorkor
No. of children (%)
Mid-upper-arm circumference — cm

10.7±0.9

10.7±1.1

−3.75±0.64†

10.7±1.1

−3.56±0.53

−3.71±0.66

No. of children (%)

197 (21.3)

186 (20.2)

195 (21.2)

Mid-upper-arm circumference — cm

10.9±1.1

11.0±1.1

10.9±1.1

−3.42±0.55

−3.49±0.58

−3.44±0.59

Weight-for-height z score
Marasmus

Weight-for-height z score
Height-for-age z score

−3.23±1.64

−3.21±1.47

−2 or lower — no./total no. (%)

Mean score

725/917 (79.1)

−3.13±1.63

756/915 (82.6)

756/910 (83.1)

−3 or lower — no./total no. (%)

490/917 (53.4)

509/915 (55.6)

504/910 (55.4)
298/920 (32.4)

HIV test performed — no./total no. (%)
Children tested

299/923 (32.4)

277/922 (30.0)

HIV-seropositive

61/298 (20.5)

60/277 (21.7)

67/296 (22.6)

HIV-seropositive and receiving ART

20/60 (33.3)

16/59 (27.1)

20/64 (31.3)

HIV-seropositive or HIV-exposed and receiving PCP
prophylaxis

30/60 (50.0)

32/60 (53.3)

39/65 (60.0)

691/922 (74.9)

687/921 (74.6)

689/917 (75.1)

121/688 (17.6)

131/684 (19.2)

136/688 (19.8)

49/117 (41.9)

59/128 (46.1)

64/129 (49.6)

Mothers tested
HIV-seropositive
HIV-seropositive and receiving ART
Known HIV infection or exposure — no. (%)

132 (14.3)

Children with kwashiorkor

82/132 (62.1)

140 (15.2)
88/140 (62.9)

148 (16.1)
79/148 (53.4)

Children with marasmic kwashiorkor

17/132 (12.9)

21/140 (15.0)

30/148 (20.3)

Children with marasmus

33/132 (25.0)

31/140 (22.1)

39/148 (26.4)

780/924 (84.4)

772/923 (83.6)

756/920 (82.2)

≥1 infectious symptom in previous 2 wk — no./total no. (%)
Fever

580/908 (63.9)

561/915 (61.3)

569/906 (62.8)

Cough

503/917 (54.9)

470/921 (51.0)

472/915 (51.6)

Diarrhea

427/918 (46.5)

445/923 (48.2)

436/914 (47.7)

791/913 (86.6)

775/916 (84.6)

780/912 (85.5)

Good appetite reported — no./total no. (%)

* Plus–minus values are means ±SD. Baseline characteristics were similar among the groups except as noted. ART denotes
antiretroviral therapy, HIV human immunodeficiency virus, and PCP Pneumocystis jiroveci pneumonia.
† P<0.05 for the comparison with cefdinir.

Baseline characteristics of the enrolled children more than 98% percent of the children reported
were similar among the three groups (Table 1, and that the child completed the entire 7-day course of
Table S1 in the Supplementary Appendix).
the study regimen (Table S2 in the Supplementary
Appendix).
STUDY INTERVENTIONS AND ADVERSE EVENTS
No cases of severe allergy or anaphylaxis were
A total of 924 children were randomly assigned identified. A total of three adverse events that
to the amoxicillin group, 923 to the cefdinir group, were presumed to be drug reactions were reportand 920 to the placebo group. Caregivers for ed: a generalized papular rash in a child who
428
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* CI denotes confidence interval.

Placebo

632
49 (7.8)
32 (5.1)
7 (1.1)
8 (1.3)
2 (0.3)

186
30 (16.1)
11 (5.9)
5 (2.7)
6 (3.2)
8 (4.3)

195
50 (25.6)
15 (7.7)
12 (6.2)
7 (3.6)
16 (8.2)

73
93
22 (30.1) 38 (40.9)
9 (12.3) 21 (22.6)
5 (6.8)
6 (6.5)
4 (5.5)
7 (7.5)
4 (5.5)
4 (4.3)

664
32 (4.8)
18 (2.7)
5 (0.8)
5 (0.8)
4 (0.6)

923
920
84 (9.1) 137 (14.9)
38 (4.1) 68 (7.4)
15 (1.6) 25 (2.7)
15 (1.6) 22 (2.4)
16 (1.7) 22 (2.4)

Amoxicillin Cefdinir

Overall
No. of children
924
Did not recover — no. (%)
104 (11.3)
Died
44 (4.8)
Withdrew from the study
20 (2.2)
Were hospitalized
26 (2.8)
Continued to have severe acute malnu- 14 (1.5)
trition
Kwashiorkor
No. of children
649
Did not recover — no. (%)
39 (6.0)
Died
15 (2.3)
Withdrew from the study
9 (1.4)
Were hospitalized
12 (1.8)
Continued to have severe acute malnu3 (0.5)
trition
Marasmic kwashiorkor
No. of children
78
Did not recover — no. (%)
24 (30.8)
Died
12 (15.4)
Withdrew from the study
6 (7.7)
Were hospitalized
4 (5.1)
Continued to have severe acute malnu2 (2.6)
trition
Marasmus
No. of children
197
Did not recover — no. (%)
41 (20.8)
Died
17 (8.6)
Withdrew from the study
5 (2.5)
Were hospitalized
10 (5.1)
Continued to have severe acute malnu9 (4.6)
trition

Outcome

1.23 (0.86–1.77)
0.89 (0.46–1.73)

1.33 (0.88–2.01)
1.47 (0.77–2.79)

1.29 (0.86–1.94)
2.19 (1.20–4.01)

1.32 (1.04–1.68)
1.55 (1.07–2.24)

0.28
0.85

0.20
0.25

0.23
0.01

0.02
0.02

Relative Risk
(95% CI)

1.59 (1.06–2.39)
1.30 (0.61–2.76)

1.36 (0.89–2.08)
1.83 (0.89–3.76)

1.61 (1.04–2.48)
1.87 (1.06–3.29)

0.02
0.55

0.19
0.11

0.04
0.03

1.29 (0.84–1.98)
1.46 (0.70–3.03)

1.02 (0.63–1.65)
1.25 (0.56–2.79)

1.25 (0.79–1.97)
0.85 (0.43–1.68)

0.29
0.33

1.00
0.64

0.39
0.73

0.14
0.57

P Value

Amoxicillin vs. Cefdinir

1.64 (1.27–2.11) <0.001 1.24 (0.94–1.62)
1.80 (1.22–2.64) 0.003 1.16 (0.76–1.77)

P Value

Relative Risk
(95% CI)

Relative Risk
(95% CI)
P Value

Placebo vs. Cefdinir

Placebo vs. Amoxicillin

Table 2. Recovery and Growth Outcomes, According to Intervention Group and Type of Severe Acute Malnutrition.*

P Value

1.38 (1.01–1.90)
1.05 (0.58–1.92)

1.34 (0.95–1.89)
1.62 (0.94–2.81)

1.43 (1.01–2.04)
2.01 (1.25–3.25)

0.05
0.87

0.13
0.12

0.06
0.005

1.46 (1.19–1.80) <0.001
1.66 (1.22–2.27) 0.002

Relative Risk
(95% CI)

Placebo vs. Amoxicillin
and Cefdinir
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received amoxicillin, thrush in a child who received cefdinir, and bloody diarrhea that resolved
spontaneously while treatment continued in a
child who received cefdinir. Children who received placebo had higher rates of cough and diarrhea reported at the first follow-up visit than
those who received an antibiotic agent; caretakers of children who received amoxicillin reported
cough least frequently, whereas children who
received cefdinir had the lowest rate of reported
diarrhea (Table S2 in the Supplementary Appendix).
NUTRITIONAL RECOVERY AND MORTALITY RATES

Overall, 88.3% of the children enrolled in the study
recovered from severe acute malnutrition (Table 2).
Children with marasmic kwashiorkor recovered
less frequently and had higher mortality rates than
children with either kwashiorkor or marasmus.
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The proportion of children who recovered was
significantly lower among those who received
placebo than among those who received either
amoxicillin (3.6 percentage points lower; 95% confidence interval [CI], 0.6 to 6.7) or cefdinir (5.8 percentage points lower; 95% CI, 2.8 to 8.7). Deaths
accounted for the largest proportion of children
who did not recover in each study group and for
each type of severe acute malnutrition. The overall mortality rate was 5.4%, but the rate was significantly higher among children who received
placebo than among those who received either
amoxicillin (relative risk, 1.55; 95% CI, 1.07 to 2.24)
or cefdinir (relative risk, 1.80; 95% CI, 1.22 to 2.64).
No significant differences in the causes of death,
as reported by verbal autopsy (i.e., a structured
investigation of events leading to the death), were
identified among the three study groups (Table S3
in the Supplementary Appendix). Although the

Table 3. Secondary Outcomes, According to Intervention Group and Type of Severe Acute Malnutrition.*
Secondary Outcome

Amoxicillin

Cefdinir

Placebo

Total

Time to recovery
No. of children
No. of days

820
30±19

839
29±19

783
30±19

29±19

Weight
No. of children
Gain (g/kg/day)†

883
3.4±4.0

897
3.9±6.3‡

873
3.1±4.1‡

3.5±4.9

Length
No. of children
Gain (mm/day)§

883
0.20±0.45

897
0.22±0.44

873
0.18±0.44

0.20±0.44

878
0.27±0.42¶

888
0.28±0.42‖

866
0.22±0.41¶‖

0.26±0.42

Time to recovery
No. of children
No. of days

610
26±16

632
27±18

583
27±17

27±17

Weight
No. of children
Gain (g/kg/day)†

636
2.7±3.4

649
3.2±6.7**

614
2.5±3.4**

2.8±4.8

Length
No. of children
Gain (mm/day)§

636
0.21±0.48

649
0.24±0.47

614
0.20±0.48

0.22±0.48

633
0.26±0.45††

642
0.26±0.42‡‡

609
0.21±0.42††‡‡

0.25±0.43

Overall

Mid-upper-arm circumference
No. of children
Gain (mm/day)§
Kwashiorkor

Mid-upper-arm circumference
No. of children
Gain (mm/day)§

430
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Table 3. (Continued.)
Secondary Outcome

Amoxicillin

Cefdinir

Placebo

Total

Time to recovery
No. of children
No. of days

54
44±21

51
39±17

55
40±18

41±19

Weight
No. of children
Gain (g/kg/day)†

65
4.1±3.4

67
4.9±4.3

76
3.6±5.1

4.2±4.4

Length
No. of children
Gain (mm/day)§

65
0.17±0.38

67
0.15±0.26

76
0.13±0.30

0.15±0.32

Mid-upper-arm circumference
No. of children
Gain (mm/day)§

63
0.22±0.33

66
0.34±0.42‡‡

75
0.19±0.37‡‡

0.25±0.38

Time to recovery
No. of children
No. of days

156
37±23

156
35±21

145
38±23

37±22

Weight
No. of children
Gain (g/kg/day)†

182
5.6±5.3

181
6.0±4.7‡‡

183
4.9±5.0‡‡

5.5±5.1

Length
No. of children
Gain (mm/day)§

182
0.15±0.33

181
0.21±0.35

183
0.16±0.32

0.17±0.34

Mid-upper-arm circumference
No. of children
Gain (mm/day)§

182
0.32±0.37

180
0.34±0.41

182
0.28±0.38

0.31±0.39

Marasmic kwashiorkor

Marasmus

*		 Plus–minus values are means ±SD. P>0.05 for all pairwise comparisons, except as noted.
†		 Weight gain was calculated from enrollment to the second follow-up visit (or to the first follow-up visit for children who
had recovered by the time of the first follow-up visit or did not return for a second follow-up visit).
‡		 P = 0.002 for the comparison of placebo with cefdinir.
§		 Gains in length and mid-upper-arm circumference were calculated from enrollment until the final study visit.
¶		 P = 0.01 for the comparison of placebo with amoxicillin.
‖		 P = 0.002 for the comparison of placebo with cefdinir.
** P = 0.02 for the comparison of placebo with cefdinir.
†† P = 0.04 for the comparison of placebo with amoxicillin.
‡‡ P = 0.03 for the comparison of placebo with cefdinir.

point estimates for nutritional recovery were higher and those for death were lower among children
who received cefdinir than among those who received amoxicillin, these differences were not significant (P = 0.22 for recovery and P = 0.53 for death,
for the comparison of amoxicillin and cefdinir by
logistic regression). Recovery rates were higher and
mortality rates were lower among children who received antibiotics than among those who received
placebo, across a number of baseline characteristics (Fig. S2 in the Supplementary Appendix).
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SECONDARY OUTCOMES

Children with marasmic kwashiorkor recovered
significantly more slowly than children with either
kwashiorkor or marasmus (Table 3). Kaplan–Meier
survival analysis for all children in the study showed
that the time to recovery was shorter in the cefdinir
group than in the amoxicillin group or the placebo group and was shorter in the amoxicillin group
than in the placebo group (Fig. 1A). Similarly, children who received an antibiotic agent survived
longer than those who received placebo (Fig. 1B).
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among children who received cefdinir than among
those who received placebo. Children who received
either antibiotic agent also had greater increases
in mid-upper-arm circumference than did those
who received placebo.

A Time to Nutritional Recovery
Amoxicillin

of

924
923
920

874
895
869

857
882
848

847
873
830

844
863
821

Figure 1. Kaplan–Meier Curves for Time to Nutritional Recovery and Time
to Death.
Kaplan–Meier curves are shown for the number of study visits until nutritional recovery was achieved (Panel A) or until death occurred (Panel B).
Recovery was defined as a weight-for-height z score of −2 or higher without
bilateral pitting edema. Follow-up visits and the distribution of ready-to-use
therapeutic food were scheduled for every 2 weeks, but some children were
brought early or late for their follow-up visits. All P values were calculated
by the log-rank test.

As compared with children who did not recover,
those who recovered were significantly older
and were more likely to have their father alive
and still in the home (Table S4 in the Supplementary Appendix). Among children with marasmus or marasmic kwashiorkor, those with
the lowest mid-upper-arm circumference and
the lowest weight-for-height z score at enrollment were most likely to have treatment failure
or to die. Children with the lowest height-forage z score were least likely to recover. Although
only 874 of 2765 children (31.6%) were tested
for HIV, those who were known to be HIV-seropositive, especially if not receiving antiretroviral therapy, had the highest risks of treatment
failure and death. Acute infectious symptoms
and poor appetite both at enrollment and at the
first follow-up visit (Table S5 in the Supplementary Appendix) were also associated with an increased risk of treatment failure.
A multiple logistic-regression model for baseline and intervention characteristics associated
with nutritional recovery showed that younger age,
marasmic kwashiorkor, greater stunting, HIV exposure or infection, and a cough before enrollment were associated with an increased risk of
treatment failure (Table 4). These factors also
proved to be significantly correlated with an increased risk of death; in addition, the caretaker’s
report of a good appetite at enrollment was significantly correlated with a reduced risk of death.
As with the results of the univariate analysis, receipt of amoxicillin or cefdinir was strongly correlated with improved outcomes, although no
significant difference between amoxicillin and
cefdinir was observed. The interaction term between the type of severe acute malnutrition and
the type of intervention proved not to be significant (P = 0.98 for nutritional recovery and
P = 0.45 for death).

DISCUSSION

Weight gain from enrollment until the second
follow-up visit (or until the one follow-up visit for Although improvements have been made in the
children with only one) was significantly higher treatment of severe acute malnutrition over the
432
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Table 4. Variables Associated with Nutritional Recovery or Death in the Multiple Logistic-Regression Models.
Variable

Nutritional Recovery

Death

Odds Ratio
(95% CI)

P Value

Odds Ratio
(95% CI)

1.007 (1.001–1.017)

0.02

0.989 (0.981–0.998)

0.01

Kwashiorkor vs. marasmic kwashiorkor

5.88 (4.15–8.33)

<0.001

0.25 (0.16–0.39)

<0.001

Marasmus vs. marasmic kwashiorkor

1.74 (1.22–2.47)

0.002

0.44 (0.28–0.71)

<0.001

Height-for-age z score, each 1.0-point increase

1.19 (1.09–1.31)

<0.001

0.78 (0.69–0.88)

<0.001

Mother or child HIV-seropositive

0.36 (0.27–0.47)

<0.001

2.01 (1.36–2.95)

<0.001

Cough during 2 wk before enrollment

0.76 (0.59–0.99)

0.04

1.52 (1.06–2.18)

0.02

Good appetite reported at enrollment*

—

—

0.51 (0.34–0.77)

0.001

Amoxicillin vs. placebo

1.38 (1.02–1.86)

0.03

0.67 (0.44–1.00)

0.05

Cefdinir vs. placebo

1.69 (1.24–2.31)

0.001

0.57 (0.37–0.88)

0.01

Age, each 1-mo increase

P Value

Intervention group

* Data for good appetite at enrollment were not significantly associated with nutritional recovery and were not included
in the regression model.

past decade, with the advent and widespread use
of RUTF, more than 1 million children per year
still die from this disease.21 Given the high incidence of severe acute malnutrition worldwide,1
the number of children who die remains unacceptably high, despite the best current, proved
treatment.27 In this double-blind, randomized,
placebo-controlled trial, we found that the routine addition of amoxicillin or cefdinir to the outpatient management of severe acute malnutrition
was associated with marked improvements in recovery and mortality rates and significant improvements in weight and gain in the mid-upperarm circumference.
A 24.4% (95% CI, 4.1 to 40.4) reduction in the
treatment-failure rate was observed when amoxicillin was added to routine therapy and a 38.9%
(95% CI, 21.1 to 52.7) reduction was observed
with cefdinir (Table 2). Moreover, a 35.6% (95%
CI, 6.9 to 55.4) reduction in the mortality rate was
observed with amoxicillin, and a 44.3% (95% CI,
18.0 to 62.2) reduction in the mortality rate was
observed with cefdinir. Secondary outcomes (Table 3) were also generally consistent with these
findings, with the shortest time to recovery and
greatest gains in weight and mid-upper-arm circumference among children who received cefdinir
and the longest time to recovery and smallest
gains in weight and mid-upper-arm circumference among those who received placebo.
This study was conducted in rural sub-Saharan
n engl j med 368;5

Africa in a stable subsistence farming population with a heavy burden of food insecurity and
HIV infection and the acquired immunodeficiency syndrome, so these results may not necessarily be applicable in other populations, and thus
they warrant validation in other contexts. However, no interaction between the type of severe
acute malnutrition and the intervention group was
observed, suggesting that this factor alone should
not invalidate the generalizability of these findings. Although only a limited number of children
had been tested for HIV, a high proportion of
infected children had treatment failure or died
(Table S4 in the Supplementary Appendix), providing further evidence for the need to provide
integrated care for HIV infection and malnutrition in such children.28,29
During this study, we pursued an aggressive
strategy to determine the clinical status of children lost to follow-up. Almost all the children
whom we were able to find had in fact died or
were so ill that they needed to be hospitalized.
This accounts for the higher percentage of
deaths in our study than in other studies in Malawi,26,30,31 in which the children were likely to
have been categorized simply as having withdrawn from the study.
The amoxicillin used in this study cost an average of $2.67 per child, and the cost of cefdinir
was $7.85 but presumably would be lower if it
were used on a large scale. For comparison, the
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cost of RUTF was approximately $50 for the
course of therapy. Caretakers reported excellent
adherence and did not report any difficulty in
administering the medications. Among the children who received antibiotics, the rates of common side effects (most notably, diarrhea) were
lower than they were among children who received placebo (Table S2 in the Supplementary
Appendix). One might speculate that this may suggest a potential mechanism of effectiveness in the
malnutrition armamentarium (i.e., decreasing the
rates of bacterial pneumonia and dehydrating diarrhea in these immunocompromised children).
The children enrolled in this study had uncomplicated severe acute malnutrition, as do the
vast majority of malnourished children who present for care,21 in that they all showed a good appetite at enrollment and no clinical signs of sepsis. The small proportion of children who did not
meet these criteria were transferred to inpatient
treatment. Mucosal defenses (both respiratory
and intestinal) are known to be compromised in
resource-limited settings such as Malawi,32 especially among malnourished children.33,34 Studies
of bacteremia in malnourished children11 suggest that most severe invasive bacterial infections
are due to translocation across these compromised mucosal surfaces. Thus, although these
children did not specifically show signs of sepsis
at the time of enrollment, antibiotics were effective in lowering the risk that these complications
would develop during nutritional treatment. Although the increasing threat of antimicrobial
resistance in the developing world35-38 cannot be
ignored and instances of highly resistant bacteria have been observed in malnourished children,39 we believe that the routine use of antibiotics is worth serious consideration because of
the observed benefits of nutritional recovery and

of

m e dic i n e

a reduced risk of death in this specific high-risk
population.
Our results suggest that children with uncomplicated severe acute malnutrition who qualify
for outpatient therapy4 remain at risk for severe
bacterial infection and that the routine inclusion
of antibiotics as part of their nutritional therapy
is warranted. This prospective, randomized,
double-blind, placebo-controlled study supplants
our previous retrospective, uncontrolled study,19
which showed no benefit of routine amoxicillin
therapy. The results of the previous study were
likely to have been confounded by the large differences in baseline characteristics between the
children who received antibiotics and those who
did not and may also have been confounded by
other, unidentified factors in the implementation
of the therapeutic feeding protocols between the
two groups. Further studies are needed to evaluate long-term outcomes of routine antibiotic use
in children with uncomplicated severe acute malnutrition and to determine whether a specific highrisk target population can be better defined.
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